Discovery of a Novel Class of Selective Non-Peptide Antagonists for the Human Neurokinin-3 Receptor. 2. Identification of (S)-N-(1-Phenylpropyl)-3-hydroxy-2- phenylquinoline-4-carboxamide (SB 223412) (original) (raw)

Abstract

Optimization of the previously reported 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonist 14, with regard to potential metabolic instability of the ester moiety and affinity and selectivity for the human neurokinin-3 (hNK-3) receptor, is described. The ester functionality could be successfully replaced by the ketone (31) or by lower alkyl groups (Et, 21, or n-Pr, 24). Investigation of the substitution pattern of the quinoline ring resulted in the identification of position 3 as a key position to enhance hNK-3 binding affinity and selectivity for the hNK-3 versus the hNK-2 receptor. All of the chemical groups introduced at this position, with the exception of halogens, increased the hNK-3 binding affinity, and compounds 53 (3-OH, SB 223412, hNK-3-CHO binding K i) 1.4 nM) and 55 (3-NH 2 , hNK-3-CHO binding K i) 1.2 nM) were the most potent compounds of this series. Selectivity studies versus the other neurokinin receptors (hNK-2-CHO and hNK-1-CHO) revealed that 53 is about 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 µM. In vitro studies demonstrated that 53 is a potent functional antagonist of the hNK-3 receptor (reversal of senktide-induced contractions in rabbit isolated iris sphincter muscles and reversal of NKB-induced Ca 2+ mobilization in CHO cells stably expressing the hNK-3 receptor), while in vivo this compound showed oral and intravenous activity in NK-3 receptor-driven models (senktide-induced behavioral responses in mice and senktide-induced miosis in rabbits). Overall, the biological data indicate that (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (53, SB 223412) may serve as a pharmacological tool in animal models of disease to assess the functional and pathophysiological role of the NK-3 receptor and to establish therapeutic indications for non-peptide NK-3 receptor antagonists.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (35)

  1. Maggi, C. A.; Patacchini, R.; Rovero, P.; Giachetti, A. Tachykinin Receptors and Tachykinin Receptor Antagonists. J. Auton. Pharmacol. 1993, 13, 23-93.
  2. Maggio, J. E. Tachykinins. Annu. Rev. Neurosci. 1988, 11, 13- 28.
  3. Giardina, G. A. M.; Raveglia, L. F.; Grugni, M. Lead generation and lead optimization processes in the discovery of selective nonpeptide neurokinin receptor antagonists. Drugs Future 1997, 22, 1235-1257.
  4. Edmonds-Alt, X.; Bichon, D.; Ducoux, J. P.; Heaulme, M.; Miloux, B.; Poncelet, M.; Proietto, V.; Van Broeck, D.; Vilain, P.; Neliat, G.; Soubrie ´, P.; Le Fur, G.; Breliere, J. C. SR 142801, the First Potent Non-Peptide Antagonist of the Tachykinin NK-3 Recep- tor. Life Sci. 1995, 56, PL 27-32.
  5. Oury-Donat, F.; Carayon, P.; Thurneyssen, O.; Pailhon, V.; Edmonds-Alt, X.; Soubrie ´, P.; Le Fur, G. Functional Character- ization of the Non-Peptide Neurokinin-3 (NK-3) Receptor An- tagonist, SR 142801 on the Human NK-3 Receptor Expressed in Chinese Hamster Ovary Cells. J. Pharmacol. Exp. Ther. 1995, 274, 148-154.
  6. Shah, S. K. U.S. Patent 5,434,158, July 18, 1995; Chem. Abstr. 123, 218432x. (b) Harrison, T.; Korsgaard, M. P. G.; Swain, C. J.; Cascieri, M. A.; Sadowski, S.; Seabrook, G. R. High Affinity, Selective Neurokinin 2 and Neurokinin 3 Receptor Antagonists from a Common Structural Template. Bioorg. Med. Chem. Lett. 1998, 8, 1343-1348.
  7. Boden, P.; Eden, J. M.; Hodgson, J.; Horwell, D. C.; Hughes, J.; McKnight, A. T.; Lewthwaite, R. A.; Pritchard, M. C.; Raphy, J.; Meecham, K.; Ratcliffe, G. S.; Suman-Chauhan, N.; Woodruff, G. N. Use of a Dipeptide Chemical Library in the Development of Non-Peptide Tachykinin NK-3 Receptor Selective Antagonists. J. Med. Chem. 1996, 39, 1664-1675.
  8. Giardina, G. A. M.; Sarau, H. M.; Farina, C.; Medhurst, A. D.; Grugni, M.; Foley J. J.; Raveglia, L. F.; Schmidt, D. B.; Rigolio, R.; Vassallo, M.; Vecchietti, V.; Hay, D. W. P. 2-Phenyl-4- quinolinecarboxamides: A Novel Class of Potent and Selective Non-Peptide Competitive Antagonists for the Human Neuroki- nin-3 Receptor. J. Med. Chem. 1996, 39, 2281-2284.
  9. Giardina, G. A. M.; Sarau, H. M.; Farina, C.; Medhurst, A. D.; Grugni, M.; Raveglia, L. F.; Schmidt, D. B.; Rigolio, R.; Lutt- mann, M.; Vecchietti, V.; Hay, D. W. P. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide frame- work. J. Med. Chem. 1997, 40, 1794-1807.
  10. Pritchard, M. C.; Boden, P. Tachykinin NK-3 receptors: Biology and development of selective peptide and nonpeptide ligands. Drugs Future 1995, 20, 1163-1173.
  11. Giardina, G. A. M.; Raveglia, L. F. Neurokinin-3 receptor antagonists. Exp. Opin. Ther. Patents 1997, 7, 307-323.
  12. Buu-Hoı ¨, P. H.; Hoa ´n; Kho ˆi, H.; Xuong, D. 7-Methylmercapto- 1-tetralone and its use in preparing sulfur-containing carbazoles and acridines. J. Org. Chem. 1950, 15, 511-516.
  13. Munson, H. R.; Johnson, R. E.; Sanders, J. M.; Ohnmacht, C. J.; Lutz, R. E. Antimalarials. 10. Substituted 3-halo-and 3-methoxy-2-aryl-4-quinoline(di-n-butylaminomethyl)metha- nols. J. Med. Chem. 1975, 18, 1232-1236.
  14. Raveglia, L. F.; Giardina, G. A. M.; Grugni, M.; Rigolio, R.; Farina, C. A novel synthesis of 3-halo-2-phenylquinoline-4- carboxylic acids. J. Heterocycl. Chem. 1997, 34, 557-559.
  15. Meyers, A. I.; Poindexter, G. S.; Brich, Z. Asymmetric synthesis of (+)-or (-)-2 methyloctanal via the metalloenamines of chiral alkoxy amines. J. Org. Chem. 1978, 43, 892-898.
  16. Dishart, K. T.; Levine, R. A new synthesis of ketones containing one perfluoroalkyl group. J. Am. Chem. Soc. 1956, 78, 2268- 2270.
  17. Barney, C. L.; Huber, E. W.; McCarthy, J. R. A convenient synthesis of hindered amines and R-trifluoromethylamines from ketones. Tetrahedron Lett. 1990, 31, 5547-5550.
  18. Kaiser, C.; Weinstock, J. Amines from mixed carboxylic-carbonic anhydrides: 1-phenylcyclopentylamine. Organic Syntheses; Wiley: New York, 1988; Coll. Vol. 6, pp 910-913.
  19. Ho ¨gberg, T.; Stro ¨m, P.; Ebner, M.; Ra ¨msby, S. Cyanide as an efficient catalyst in the aminolysis of esters. J. Org. Chem. 1987, 52, 2033-2036.
  20. Omura, K.; Swern, D. Oxidation of alcohols by activated dimethyl sulfoxide. A preparative, steric and mechanistic study. Tetra- hedron 1978, 34, 1651-1660.
  21. Soai, K.; Oyamada, H.; Okawa, A. Sodium borohydride-tert-butyl alcohol-methanol as an efficient system for the selective reduc- tion of esters. Synth. Commun. 1982, 12, 463-467.
  22. Sarau, H. M.; Griswold, D. E.; Potts, W.; Foley, J. J.; Schmidt, D. B.; Webb, E. F.; Martin, L. D.; Brawner, M. E.; Elshourbagy, N. A.; Medhurst, A. D.; Giardina, G. A. M.; Hay, D. W. P. Nonpeptide tachykinin receptor antagonists. I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective NK-3 receptor antagonist. J. Pharmacol. Exp. Ther. 1997, 281, 1303-1311.
  23. Sadowski, S.; Huang, R.-R. C.; Fong, T. M.; Marko, O.; Cascieri, M. A. Characterization of the Binding of [ 125 I-Iodo-histidyl,- methyl-Phe 7 ] Neurokinin B to the Neurokinin-3 Receptor. Neu- ropeptides 1993, 24, 317-319.
  24. Cheng, Y.-C.; Prusoff, W. H. Relationship Between the Inhibition Constant (Ki) and the Concentration of Inhibitor Which Cause 50 Percent Inhibition (IC50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
  25. Aharony, D.; Conner, G. E.; Woodhouse, D. P. Pharmacologic Characterization of the Novel Ligand [4,5-3 H-Leu 9 ]-Neurokinin- A Binding to NK-2 Receptors on Hamster Urinary Bladder Membranes. Neuropeptides 1992, 23, 121-130.
  26. Payan, D. G.; McGillis, J. P.; Organist, M. L. Binding Charac- teristics and Affinity Labeling of Protein Constituents of the Human IM-9 Lymphoblast Receptor for Substance P. J. Biol. Chem. 1986, 26, 14321-14329.
  27. Hall, J. M.; Mitchell, D.; Morton, I. K. M. Neurokinin Receptors in the Rabbit Iris Sphincter Characterised by Novel Agonist Ligands. Eur. J. Pharmacol. 1993, 199, 9-14.
  28. a) Medhurst, A. D.; Hay, D. W. P.; Parsons, A. A. Evidence for NK 3 Receptor Subtypes in Rabbit Isolated Iris Sphincter Muscle Using the NK3 Receptor Antagonists SR 142801 and SR 48968. Br. J. Pharmacol. 1996, 117, 203P. (b) Medhurst, A. D.; Parsons, A. A.; Roberts, J. C.; Hay, D. W. P. Characterization of NK-3 Receptors in Rabbit Isolated Iris Sphincter Muscle. Br. J. Pharmacol. 1997, 120, 93-101.
  29. Jenkinson, D. H.; Barnard, E. A.; Hoyer, D.; Humphrey, P. P. A.; Leff, P.; Shankley, N. P. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on Terms and Symbols in Quantitative Pharmacology. Pharmacol. Rev. 1995, 47, 255-266.
  30. Grynkiewicz, G.; Poenie, M.; Tsein, R. Y. A New Generation of Ca 2+ Indicators with Greatly Improved Fluorescence Properties. J. Biol. Chem. 1985, 260, 3440-3450.
  31. Stoessl, A. J.; Dourish, C. T.; Iversen, S. D. The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behavior fol- lowing central or peripheral administration in mice and rats. Br. J. Pharmacol. 1988, 94, 285-287.
  32. Stoessl, A. J.; Dourish, C. T.; Iversen, S. D. Pharmacological charcterization of the behavioural syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT. Brain Res. 1990, 517, 111-116.
  33. Beding-Barnekow, B.; Brodin, E.; Hakanson, R. Substance P, neurokinin A and neurokinin B in the ocular response to injury in the rabbit. Br. J. Pharmacol. 1988, 95, 259-267.
  34. Medhurst, A. D.; Hay, D. W. P.; Parsons, A. A.; Martin, L. D.; Griswold, D. E. In vitro and in vivo characterisation of NK-3 receptors in the rabbit eye by use of selective non-peptide NK-3 receptor antagonists. Br. J. Pharmacol. 1997, 122, 469-476.
  35. Grugni, M.; Farina, C.; Giardina, G. A. M.; Raveglia, L. F.; Sarau, H. M.; Schmidt, D. B.; Vecchietti, V.; Hay, D. W. P. Potent and selective non-peptide NK-3 receptor antagonists based on the quinoline framework. Poster presented at the XIVth Interna- tional Symposium on Medicinal Chemistry, Maastricht, The Netherlands, Sept 1996; Book Abstr. P-2.15.